Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma

REFERENCES

1. 1.↵
   1. Stupp R,
   2. Mason WP,
   3. van den Bent MJ,
   4. et al

   . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Hu LS,
   2. Eschbacher JM,
   3. Heiserman JE,
   4. et al

   . Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol 2012;14:919–30

   Abstract/FREE Full Text
3. 3.↵
   1. Verhaak RG,
   2. Hoadley KA,
   3. Purdom E,
   4. et al

   . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98–110

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Phillips HS,
   2. Kharbanda S,
   3. Chen R,
   4. et al

   . Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157–73

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Lal A,
   2. Glazer CA,
   3. Martinson HM,
   4. et al

   . Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002;62:3335–39

   Abstract/FREE Full Text
6. 6.↵
   1. Mazzoleni S,
   2. Politi LS,
   3. Pala M,
   4. et al

   . Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 2010;70:7500–13

   Abstract/FREE Full Text
7. 7.↵
   1. Schlegel J,
   2. Merdes A,
   3. Stumm G,
   4. et al

   . Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994;56:72–77

   PubMedWeb of Science
8. 8.↵
   1. Ohgaki H,
   2. Kleihues P

   . Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445–53

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Halatsch ME,
   2. Schmidt U,
   3. Behnke-Mursch J,
   4. et al

   . Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006;32:74–89

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Ramis G,
    2. Thomas-Moya E,
    3. Fernandez de Mattos S,
    4. et al

    . EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth. PLoS One 2012;7:e38770

    CrossRefPubMed
11. 11.↵
    1. Barajas RF Jr.,
    2. Rubenstein JL,
    3. Chang JS,
    4. et al

    . Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2010;31:60–66

    Abstract/FREE Full Text
12. 12.↵
    1. Bulakbasi N,
    2. Guvenc I,
    3. Onguru O,
    4. et al

    . The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors. J Comp Assist Tomogr 2004;28:735–46

    CrossRefPubMed
13. 13.↵
    1. Calli C,
    2. Kitis O,
    3. Yunten N,
    4. et al

    . Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006;58:394–403

    CrossRefPubMed
14. 14.↵
    1. Castillo M,
    2. Smith JK,
    3. Kwock L,
    4. et al

    . Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001;22:60–64

    Abstract/FREE Full Text
15. 15.↵
    1. Gupta A,
    2. Young RJ,
    3. Karimi S,
    4. et al

    . Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol 2011;32:1301–06

    Abstract/FREE Full Text
16. 16.↵
    1. Mills SJ,
    2. Soh C,
    3. Rose CJ,
    4. et al

    . Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging–derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. AJNR Am J Neuroradiol 2010;31:549–53

    Abstract/FREE Full Text
17. 17.↵
    1. Young RJ,
    2. Gupta A,
    3. Shah AD,
    4. et al

    . Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 2011;76:1918–24

    CrossRef
18. 18.↵
    1. Barajas RF Jr.,
    2. Phillips JJ,
    3. Parvataneni R,
    4. et al

    . Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging. Neuro Oncol 2012;14:942–54

    Abstract/FREE Full Text
19. 19.↵
    1. Pope WB,
    2. Kim HJ,
    3. Huo J,
    4. et al

    . Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182–89

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Lee EJ,
    2. terBrugge K,
    3. Mikulis D,
    4. et al

    . Diagnostic value of peritumoral minimum apparent diffusion coefficient for differentiation of glioblastoma multiforme from solitary metastatic lesions. AJR Am J Roentgenol 2011;196:71–76

    CrossRefPubMed
21. 21.↵
    1. Wetzel SG,
    2. Cha S,
    3. Johnson G,
    4. et al

    . Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Law M,
    2. Young R,
    3. Babb J,
    4. et al

    . Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. AJNR Am J Neuroradiol 2007;28:761–66

    Abstract/FREE Full Text
23. 23.↵
    1. Diehn M,
    2. Nardini C,
    3. Wang DS,
    4. et al

    . Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 2008;105:5213–18

    Abstract/FREE Full Text
24. 24.↵
    1. Carrillo JA,
    2. Lai A,
    3. Nghiemphu PL,
    4. et al

    . Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 2012;33:1349–55

    Abstract/FREE Full Text
25. 25.↵
    1. Bruzzone MG,
    2. Eoli M,
    3. Cuccarini V,
    4. et al

    . Genetic signature of adult gliomas and correlation with MRI features. Expert Rev Molecular Diagn 2009;9:709–20

    CrossRef
26. 26.↵
    1. Tykocinski ES,
    2. Grant RA,
    3. Kapoor GS,
    4. et al

    . Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol 2012;14:613–23

    Abstract/FREE Full Text
27. 27.↵
    1. Gupta A,
    2. Omuro AM,
    3. Shah AD,
    4. et al

    . Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology 2012;54:641–43

    CrossRefPubMed
28. 28.↵
    1. Jain R,
    2. Poisson L,
    3. Narang J,
    4. et al

    . Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology 2013;267:212–20

    CrossRefPubMed
29. 29.↵
    1. Pope WB,
    2. Mirsadraei L,
    3. Lai A,
    4. et al

    . Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol 2012;33:1059–64

    Abstract/FREE Full Text
30. 30.↵
    1. Jain R,
    2. Poisson L,
    3. Narang J,
    4. et al

    . Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: a feasibility study. AJNR Am J Neuroradiol 2012;33:1343–48

    Abstract/FREE Full Text
31. 31.↵
    1. Choi BD,
    2. Archer GE,
    3. Mitchell DA,
    4. et al

    . EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009;19:713–23

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Aghi M,
    2. Gaviani P,
    3. Henson JW,
    4. et al

    . Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11:8600–05

    Abstract/FREE Full Text
33. 33.↵
    1. Goldman CK,
    2. Kim J,
    3. Wong WL,
    4. et al

    . Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4:121–33

    Abstract/FREE Full Text
34. 34.↵
    1. Kono K,
    2. Inoue Y,
    3. Nakayama K,
    4. et al

    . The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001;22:1081–88

    Abstract/FREE Full Text
35. 35.↵
    1. Schaefer PW,
    2. Grant PE,
    3. Gonzalez RG

    . Diffusion-weighted MR imaging of the brain. Radiology 2000;217:331–45

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Rieger J,
    2. Bähr O,
    3. Müller K,
    4. et al

    . Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 2010;99:49–56

    CrossRefPubMed
37. 37.↵
    1. Wang X,
    2. Schneider A

    . HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 2010;31:1202–10

    Abstract/FREE Full Text
38. 38.↵
    1. Franovic A,
    2. Holterman CE,
    3. Payette J,
    4. et al

    . Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A 2009;106:21306–11

    Abstract/FREE Full Text
39. 39.↵
    1. Ronellenfitsch MW,
    2. Brucker DP,
    3. Burger MC,
    4. et al

    . Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain 2009;132:1509–22

    Abstract/FREE Full Text
40. 40.↵
    1. Steinbach JP,
    2. Klumpp A,
    3. Wolburg H,
    4. et al

    . Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res 2004;64:1575–78

    Abstract/FREE Full Text
41. 41.↵
    1. Kesavabhotla K,
    2. Schlaff CD,
    3. Shin B,
    4. et al

    . Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. J Exp Ther Oncol 2012;10:71–81

    PubMed
42. 42.↵
    1. Prados MD,
    2. Chang SM,
    3. Butowski N,
    4. et al

    . Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009;27:579–84

    Abstract/FREE Full Text
43. 43.↵
    1. Brandes AA,
    2. Franceschi E,
    3. Tosoni A,
    4. et al

    . Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res 2008;14:957–60

    Abstract/FREE Full Text
44. 44.↵
    1. Wachsberger PR,
    2. Lawrence YR,
    3. Liu Y,
    4. et al

    . Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. Int J Radiat Oncol Biol Phys 2012;82:483–91

    CrossRefPubMed
45. 45.↵
    1. Kreisl TN,
    2. McNeill KA,
    3. Sul J,
    4. et al

    . A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol 2012;14:1519–26

    Abstract/FREE Full Text
46. 46.↵
    1. Barkovich KJ,
    2. Hariono S,
    3. Garske AL,
    4. et al

    . Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov 2012;2:450–57

    Abstract/FREE Full Text
47. 47.↵
    1. Mellinghoff IK,
    2. Wang MY,
    3. Vivanco I,
    4. et al

    . Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012–24

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Haas-Kogan DA,
    2. Prados MD,
    3. Tihan T,
    4. et al

    . Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880–87

    Abstract/FREE Full Text
49. 49.↵
    1. Park JH,
    2. Lemmon MA

    . Occupy EGFR. Cancer Discov 2012;2:398–400

    Abstract/FREE Full Text
50. 50.↵
    1. Hamstra DA,
    2. Galban CJ,
    3. Meyer CR,
    4. et al

    . Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008;26:3387–94

    Abstract/FREE Full Text
51. 51.↵
    1. Moffat BA,
    2. Chenevert TL,
    3. Lawrence TS,
    4. et al

    . Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524–29

    Abstract/FREE Full Text
52. 52.↵
    1. El Naqa I,
    2. Grigsby P,
    3. Apte A,
    4. et al

    . Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit 2009;42:1162–71

    CrossRefPubMed